Reviews/Targeted Therapy Prostate Cancer/Denosumab skeletal-related event prevention in metastatic castration-resistant prostate cancer
Bone · PC-BONE-02 · v2
Borderline: within 4 points of the Established/Likely boundary, so a re-grade could land either side.
In men whose prostate cancer has spread to bone and no longer responds to hormone therapy, the question is whether denosumab both postpones bone complications and does so better than the older drug zoledronic acid. The corpus contains one large head-to-head trial in exactly this group [2] that compared the two drugs and found denosumab pushed back the time to a first bone complication and reduced repeat complications. A later analysis that grouped several trials together [5] found the same direction of benefit held in prostate-cancer patients. A separate trial in other cancers [1] found denosumab only matched, rather than beat, zoledronic acid, which keeps the stronger claim tied to this prostate-cancer setting. The panel treated the prostate trial as directly answering both parts of the claim, while noting the benefit is for bone events only and the margin is not large.
The pivotal randomised double-blind active-controlled trial in metastatic castration-resistant prostate cancer [2] (n=1,901) reports denosumab delayed time to first on-study skeletal-related event versus zoledronic acid (median 20.7 vs 17.1 months, a difference of 3.6 months; HR 0.82, 95% CI 0.71, 0.95; p=0.008) and delayed first and subsequent events (HR 0.82, 95% CI 0.71, 0.94; p=0.004). A pooled analysis of three phase III trials [5] (N=5,543) reports denosumab significantly reduced the risk of first SRE across subgroups including prostate cancer (HR ranges such as 0.73-0.86). The contrasting trial in advanced cancer excluding breast and prostate [1] reports only noninferiority (HR 0.84, 95% CI 0.71 to 0.98) and explicitly not superiority (P=.03 unadjusted; P=.06 adjusted). The remaining corpus is preclinical, cost-effectiveness or review material and does not test the comparison. The contested point: The division is over independence and interpretation, not direction: the direct prostate-cancer superiority result [2] is a single ASCO conference abstract, and the pooled analysis [5] re-uses the same trial data rather than replicating it independently. The benefit is also confined to the composite bone-event endpoint, since [2] reports no overall-survival (HR 1.03, p=0.65) or progression (HR 1.06, p=0.30) advantage.
All 15 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Targeted Therapy Prostate Cancer, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The direct mCRPC superiority evidence [2] is a single ASCO conference abstract in this corpus, not a full peer-reviewed article, so the primary data cannot be fully interrogated here.
The pooled analysis [5] re-uses the same phase III CRPC trial data as [2]; it is not independent replication, so apparent dual support is largely one trial.
Where it remains uncertain. The direct evidence [2] is a conference abstract and the pooled analysis [5] is not independent of it, while [2] itself shows no survival or progression benefit and numerically more osteonecrosis of the jaw (2.3% vs 1.3%).
Aleatory
The benefit in [2] is a 3.6-month median delay in time to first SRE; individual patient outcomes vary around this median and some events are not prevented.
Epistemic
The direct mCRPC result [2] exists in the corpus only as an ASCO conference abstract (LBA4507), so the primary trial data cannot be fully interrogated.
Inferential
Superiority holds for the composite SRE endpoint only; [2] reports no overall-survival (HR 1.03, p=0.65) or progression (HR 1.06, p=0.30) benefit, so the result cannot be read as clinical or survival superiority.
The load-bearing papers from a corpus of 15, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Boundary evidence showing superiority is not universal across tumour types, scoping the claim to mCRPC.
“Although directionally favorable, denosumab was not statistically superior to ZA in delaying time to first on-study SRE (P = .03 unadjusted; P = .06 adjusted for multiplicity)”
Panel auditInternal validity: high · scope of inference: Patients with advanced cancer and bone metastases excluding breast and prostate, or myeloma.Key limitations: prostate cancer explicitly excluded · superiority not met in this population
Direct pivotal-trial evidence in the exact population and endpoint establishing both delay of SREs and superiority over ZA.
“Denosumab demonstrated superiority over ZA in delaying or preventing SREs in patients with bone metastases from CRPC.”
Panel auditInternal validity: high · scope of inference: Men with metastatic CRPC and at least one bone metastasis, no prior IV bisphosphonate.Key limitations: conference abstract (LBA) · no overall-survival or progression benefit · more hypocalcaemia and numerically more ONJ with denosumab
Pooled confirmation that superiority for first SRE is consistent across subgroups, though drawn from the same underlying trial data.
“Compared with ZA, denosumab significantly reduced the risk of first SRE across all subgroups (hazard ratio [HR] ranges: ECOG PS, 0.79-0.84; bone metastasis location, 0.78-0.83; bone metastasis number, 0.78-0.84; visceral metastasis presence/absence, 0.80-0.82; uNTx level, 0.73-0.86)”
Panel auditInternal validity: medium · scope of inference: Breast, prostate, and other solid-tumour patients with bone metastases, analysed by baseline characteristics.Key limitations: post-hoc subgroup analysis · prostate result pooled with other tumours · mCRPC-specific HR not stated
3 of 15 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
A large double-blind active-controlled RCT tests the exact population and endpoint and shows superiority, so the corpus genuinely carries the verdict despite the direct evidence being a conference abstract and the pooled analysis not being independent of it.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Full peer-reviewed report of the mCRPC trial. The direct superiority finding rests on an ASCO abstract [2]; the complete trial publication is absent from the corpus. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: Add the full peer-reviewed primary publication of the denosumab-versus-zoledronic-acid mCRPC phase III trial so the primary endpoint data can be interrogated.
Open question: Does the mCRPC superiority of denosumab over zoledronic acid replicate in an independent trial not drawn from the same phase III dataset? Why it is still open: Both [2] and [5] rely on the same underlying trial, so the corpus contains no independent confirmation.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 26 Oct 2026 · protocol v0.19